Entity

Time filter

Source Type

Baton Rouge, LA, United States

The invention relate to methods, compositions, and kits for reprogramming a cell. In one embodiment, the invention relates to a method comprising inducing the expression of at least one gene that contributes to a cell being pluripotent or multipotent. In yet another embodiment, the method comprises delivering a transcription factor to a cell and exposing said cell to an agent that inhibits the activity, expression, or activity and expression of a gene, which codes for a protein, or a protein involved in transcriptional repression, and selecting a cell, wherein differentiation potential has been restored to said cell. In yet another embodiment, the invention relates to a reprogrammed cell and an enriched population of reprogrammed cells that can have characteristics of an ES-like cell can be re- or trans-differentiated into various differentiated cell types.


Grant
Agency: Department of Health and Human Services | Branch: | Program: SBIR | Phase: Phase I | Award Amount: 0.00 | Year: 2005

DESCRIPTION (provided by applicant): Infigen will use SBIR grant support to develop a model for evaluating the molecular events associated with cellular reprogramming that enables early determination of a cell's probability of developing into a desired organism or tissue. No such model has been reported to date, impeding rational approaches to development of emerging health care applications dependent upon proper reprogramming, such as cell based therapeutics and nuclear transfer technologies. Infigen's proposed model will focus on bovine and pig embryos that are candidates for nuclear transfer and will provide the ability to systematically classify the cells of such embryos for developmental competence--the ability to develop to live birth. However, the model will be designed for applications to all cell types, providing a means to assess the ability of cells to dedifferentiate and re-differentiate into specific desired cell types and tissues. Phase I studies will identify genes reflecting reprogramming competence and confirm that donor cell lines of known classes can be distinguished based on protein expression patterns. Results from these studies will be used in Phase II to develop a donor cell line reprogramming "chip" that can predict the competence of a donor cell line to be reprogrammed. The technology will be commercialized through applications in Infigen's own proprietary nuclear transfer cloning technologies for biopharmaceutical production, xenotransplantation, and animal research models, and through strategic alliances with firms developing various applications that can take advantage of the new platform, particularly cell-based therapeutics.


Grant
Agency: Department of Health and Human Services | Branch: | Program: SBIR | Phase: Phase II | Award Amount: 844.72K | Year: 2005

DESCRIPTION (provided by applicant): Infigen will use SBIR grant support to develop a model for evaluating the molecular events associated with cellular reprogramming that enables early determination of a cell's probability of developing into a desired organism or tissue. No such model has been reported to date, impeding rational approaches to development of emerging health care applications dependent upon proper reprogramming, such as cell based therapeutics and nuclear transfer technologies. Infigen's proposed model will focus on bovine and pig embryos that are candidates for nuclear transfer and will provide the ability to systematically classify the cells of such embryos for developmental competence--the ability to develop to live birth. However, the model will be designed for applications to all cell types, providing a means to assess the ability of cells to dedifferentiate and re-differentiate into specific desired cell types and tissues. Phase I studies will identify genes reflecting reprogramming competence and confirm that donor cell lines of known classes can be distinguished based on protein expression patterns. Results from these studies will be used in Phase II to develop a donor cell line reprogramming "chip" that can predict the competence of a donor cell line to be reprogrammed. The technology will be commercialized through applications in Infigen's own proprietary nuclear transfer cloning technologies for biopharmaceutical production, xenotransplantation, and animal research models, and through strategic alliances with firms developing various applications that can take advantage of the new platform, particularly cell-based therapeutics.


NuPotential | Entity website

Louisiana Emerging Technology Center, 340, E. Parker Blvd ...


Louisiana Emerging Technology Center, 340, E. Parker Blvd ...

Discover hidden collaborations